Budenofalk rectal foam for ulcerative colitis

Dr Falk has launched Budenofalk (2mg budesonide) rectal foam, indicated for treatment of active ulcerative colitis limited to the rectum and sigmoid colon.

The new presentation is available as a canister containing 14 days’ treatment of budesonide foam (2mg per actuation). The recommended dosage for adults over 18 years is one actuation daily.

Treatment with Budenofalk rectal foam results in lower systemic steroid levels than oral therapy with systemic steroids. Transfer from other steroid therapy may result in symptoms relating to the change in systemic steroid levels.

Budenofalk is also available as 3mg capsules indicated for mild to moderate Crohn’s disease affecting the ileum and/or ascending colon and symptomatic relief of chronic diarrhoea due to collagenous colitis.

Further information: Dr Falk 01628 536600

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New antibiotic prescribing guidance issued for pneumonia

New antibiotic prescribing guidance issued for pneumonia

NICE has published antimicrobial prescribing guidelines...

MIMS summary of NICE COPD guidance updated

MIMS summary of NICE COPD guidance updated

Prescribers can now consult the quick-reference MIMS...

Soft-mist inhaler now available as reusable device

Soft-mist inhaler now available as reusable device

Respimat is now available as a reusable inhaler that...

NICE recommends 'innovative' treatment for type I diabetes

NICE recommends 'innovative' treatment for type I diabetes

Dapagliflozin (Forxiga) has been approved for routine...